Antimicrobial Resistance Lab Network
Carbapenem-Resistant Pseudomonas aeruginosa
Number of CRPA Isolates Tested
109,533
2017 – 2024
Percentage of CRPA with at least one targeted Carbapenemase Gene Detected
2.6%
2,848 CRPA with carbapenemase gene detected / 109,533 CRPA isolates tested
Most Common Carbapenemase in CP-CRPA
60.15% VIM
1,713 CRPA with VIM / 2,848 CP-CRPA
AR Lab Network Priority Area
Carbapenem-Resistant Pseudomonas aeruginosa
Pseudomonas aeruginosa causes many types of healthcare-associated infections, especially among people in the hospital or with weakened immune systems. It is particularly dangerous for patients with chronic lung diseases.
Carbapenem-resistant Pseudomonas aeruginosa (CRPA) organisms can carry carbapenemase genes located on mobile genetic elements that produce a carbapenemase enzyme. These enzymes make carbapenem antibiotics ineffective. Mobile genetic elements are easily shared between bacteria, rapidly spreading resistance that degrades these important drugs. CP is defined as having at least one carbapenemase gene detected. CDC targets CP-CRPA for detection and response because they spread easily and are difficult to treat.
The AR Lab Network routinely performs phenotypic testing to detect the presence of carbapenemase activity and molecular testing to identify the presence of the following five targeted carbapenemase genes:
- Klebsiella pneumoniae Carbapenemase (KPC)
- New Delhi Metallo-beta-lactamase (NDM)
- Verona Integron-encoded Metallo-beta-lactamase (VIM)
- Imipenemase Metallo-beta-lactamase (IMP)
- Oxacillinase-48-like beta-lactamase (OXA-48)
AR Lab Network data are presented in both aggregated and year-to-year formats. The AR Lab Network is not a traditional surveillance system; changes in year-to-year carbapenemase rates may also be reflective of year-to-year changes in testing priorities, methods, or volume, jurisdictional reporting criteria, and other factors. Year classification is defined by specimen collection date.
Carbapenemase Detection
Carbapenemases Detected in CRPA or CP-CRPA, by All Years
Select data visualizations using the tabs above to view denominator or isolate type data. This graph displays the distribution of carbapenemases detected among CRPA and CP-CRPA isolates. Isolates with Other CP activity were positive for carbapenemase activity but negative for all five targeted genes (KPC, NDM, VIM, IMP, OXA-48), and thus a different carbapenemase or resistance mechanism is likely responsible for the carbapenemase activity detected.
Geographic Locations
Carbapenemase Genes Detected in CRPA or CP-CRPA, by All Years and State
Select data visualizations using the tabs above to view denominator or isolate type data. This map displays the percentage of CRPA or CP-CRPA with targeted gene detected, by state, from 2017 - 2024.
Carbapenemases Detected in CRPA or CP-CRPA, by All Years and Region
Select data visualizations using the tabs above to view denominator or isolate type data. This graph displays the distribution of carbapenemases detected among CRPA and CP-CRPA isolates, by AR Lab Network Region, from 2017 - 2024. Isolates with Other CP activity were positive for carbapenemase activity but negative for all five targeted genes (KPC, NDM, VIM, IMP, OXA-48), and thus a different carbapenemase or resistance mechanism is likely responsible for the carbapenemase activity detected. View a map of the AR Lab Network regions on the CDC website.
Antimicrobial Susceptibility to Carbapenem Drugs
Susceptibility to carbapenem drugs, by carbapenemase gene, 2017 - 2024
This table shows the percentage of CRPA isolates that were not susceptible or had an intermediate or resistant interpretation for each carbapenem tested, by the presence or absence of a targeted carbapenemase gene. These data may be used by public health officials to recommend specific phenotypic definitions that will enhance reporting and submission of clinical isolates to public health for enhanced detection and surveillance of carbapenemase genes. This table is not intended to provide any information to assist with clinical decision making.
Antimicrobial susceptibility testing results were interpreted using the most current version of the CLSI M100 document for breakpoints where available.
* Isolates positive for more than one carbapenemase gene and isolates positive for carbapenemase activity but negative for all five targeted carbapenemase genes were excluded from the analysis.
Footnotes
- The AR Lab Network was not designed to be a traditional surveillance system. Isolates tested are a convenience sample and include clinical, surveillance, and outbreak specimens. Within each state, isolate submissions and testing are determined by state priorities and reporting regulations.
- A map of the AR Lab Network regions is available at https://www.cdc.gov/antimicrobial-resistance-laboratory-networks/php/about/.
- CP Isolates are defined as those testing positive for carbapenemase activity and/or any of the five targeted genes (KPC, NDM, VIM, IMP, OXA-48).
- Carbapenem-resistant Enterobacterales (CRE) isolates were resistant to ertapenem, imipenem, meropenem, or doripenem using antimicrobial susceptibility testing breakpoints.
- Carbapenem-resistant Pseudomonas aeruginosa (CRPA) isolates were resistant to imipenem, meropenem, or doripenem, using antimicrobial susceptibility testing breakpoints.
- Carbapenem-resistant Acinetobacter baumannii (CRAB) isolates were resistant to imipenem, meropenem, or doripenem, using antimicrobial susceptibility testing breakpoints.
- Carbapenemase gene screens aimed to detect colonization with bacteria carrying at least one of five targeted carbapenemase genes. Screens were positive when at least one of five targeted carbapenemase genes (KPC, NDM, VIM, IMP, OXA-48) was detected using real-time polymerase chain reaction (PCR).
- Suggested Citation: CDC. Antibiotic Resistance & Patient Safety Portal (AR&PSP) AR Lab Network Data. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC. https://arpsp.cdc.gov/.
- Data displayed are updated as of June 2025. Given the structure of the AR Lab Network and its testing strategies, supplementary testing and the availability of improved methods and additional data may result in changes or corrections to data reported on PSP.